Covidien closes enrollment in iliac stent studies
February 21, 2013 by Sony Salzman
Covidien closes enrollment in a pair of clinical trials, Visibility and Durability, examining its iliac stents for treating peripheral artery disease.
Covidien (NYSE:COV) said it closed enrollment in a pair of its Visibility and Durability iliac stent clinical studies.
The prospective, multinational studies are designed to compare balloon stents with self-expanding stents in the iliac arteries for treating peripheral artery disease.
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- FDA Issues Draft Guidance to Help Companies Distinguish Between a Voluntary Medical Device Recall and a Product Enhancement
- Patient and family engagement in ICUs
- A day in the life: A pediatric neurosurgeon's vision
- Medical Device Tax: Are Conservatives' goals hampering repeal efforts?
- Personal health record use by adolescents
- Can Johnson & Johnson fire on all cylinders again?
- U.S. FDA to require proof of IEC 60601-1 3rd Edition in summer 2013
- A cure for coffee breath?
- A Goldilocks approach to leaky blood vessels: Not too stiff, but not too loose
- Optimizing electronic medication administration records
Navigation
NEWS
EuroPCR: New data showing reduced mortality in InspireMD's MGuard stent trial
InspireMD presents new 6 month follow-up data showing better survival rates for its MGuard stent
Symbios recalls GoPump and GOBlock kits following patient complaints
Symbios Medical Products recalls 2 years' worth of its GoPump systems and GOBlock kits after...
Covidien launches its new respiratory monitoring device
Covidien's MicroStream MicroPod respiratory monitoring module hits the shelves
New Xbox One Kinect game system can measure heartbeat visually | MassDevice.com On Call
The newly unveiled iteration of the Microsoft Xbox One's Kinect camera demonstrates the ability to...
MassDevice.com +3 | The top 3 med-tech stories for May 22, 2013
If you read nothing else today, make sure you're still in the know with MassDevice +3.
